Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection
Abstract
Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection Arthur Poncelet, Gil Verschelden, Martin Colard, Marc Hildebrand, Maya Hites, Nicolas Yin, Charlotte Michel, David Grimaldi & Virginie De Wilde To cite this article: Arthur Poncelet, Gil Verschelden, Martin Colard, Marc Hildebrand, Maya Hites, Nicolas Yin, Charlotte Michel, David Grimaldi & Virginie De Wilde (2021): Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection, Leukemia & Lymphoma, DOI: 10.1080/10428194.2021.1978086 To link to this article: https://doi.org/10.1080/10428194.2021.1978086
Read the paper
Related studies
- In silico strategies for modeling RNA aptamers and predicting binding sites of their molecular targets
- Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery
- Anti-phytopathogenic and plant growth promoting potential of endophytic fungi isolated from Dysoxylum gotadhora
- Mercury toxicity causes iron and sulfur deficiencies along with oxidative injuries in alfalfa (Medicago sativa)
- Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p/OXSR1 axis in vitro and in vivo
- Assessing the Protective Effect of Moringa oleifera Extract against Bone Metastasis: An In Vitro Simulated Digestion Approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.